机构：[1]Peking Univ First Hosp, Beijing, Peoples R China[2]Second Affiliated Hosp Chongq, Chongqing, Peoples R China[3]Mengchao Hepatobiliary Hosp Fujia, Fuzhou, Peoples R China[4]First Affiliated Hosp Guangxi, Guangxi, Peoples R China[5]First Peoples Hosp Yunnan, Kunming, Yunnan, Peoples R China云南省第一人民医院[6]Second Affiliated Hosp Nancha, Nanchang, Jiangxi, Peoples R China[7]First Affiliated Hosp Xinjian, Urumqi, Peoples R China[8]First Affiliated Hosp Shihezi, Shihezi, Peoples R China[9]Capital Med Univ, Beijing, Peoples R China[10]Hebei Med Univ, Hosp 3, Shijiazhuang, Hebei, Peoples R China[11]Lanzhou Univ, Hosp 1, Lanzhou, Peoples R China[12]First Affiliated Hosp Shanxi, Taiyuan, Peoples R China[13]Beijing Friendship Hosp, Beijing, Peoples R China首都医科大学附属北京友谊医院
出处：
ISSN：
摘要：
Background: Hepatitis B virus (HBV) infection and
hepatitis C virus (HCV) infection are among the
leading causes of chronic liver diseases worldwide.
Through the same transmission route, HBV/HCV coinfection (HBV/HCV dual infection) widely exists and
aggravates severe liver damage. In this study, we
assessed the safety and efficacy of sofosbuvir/
velpasvir (SOF/VEL) in HBV/HCV co-infection
patients, and evaluated prophylactic use of tenofovir
alafenamide fumarate (TAF) on HBV reactivation.
第一作者机构：[1]Peking Univ First Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Han Yifan,Lin Ning,Zhang Dazhi,et al.EVALUATING THE SAFETY AND EFFICACY OF SOF/VEL TREATMENT AND PROPHYLACTIC USE OF TAF IN PATIENTS WITH CHRONIC HBV/HCV COINFECTION: A MULTICENTER STUDY[J].HEPATOLOGY.2024,80:S1087-S1088.
APA：
Han, Yifan,Lin, Ning,Zhang, Dazhi,Huang, Zuxiong,Su, Minghua...&Xu, Xiaoyuan.(2024).EVALUATING THE SAFETY AND EFFICACY OF SOF/VEL TREATMENT AND PROPHYLACTIC USE OF TAF IN PATIENTS WITH CHRONIC HBV/HCV COINFECTION: A MULTICENTER STUDY.HEPATOLOGY,80,
MLA：
Han, Yifan,et al."EVALUATING THE SAFETY AND EFFICACY OF SOF/VEL TREATMENT AND PROPHYLACTIC USE OF TAF IN PATIENTS WITH CHRONIC HBV/HCV COINFECTION: A MULTICENTER STUDY".HEPATOLOGY 80.(2024):S1087-S1088
医学